"Large Firms" China Merchants Securities initiates coverage on Kanion Pharmaceutical, expects the impact of centralized procurement to be digestedAASTOCKS·Jan 20 at 08:32 PM512290+0.60%516500+0.65%
Kanion Pharmaceutical: Wholly-owned subsidiary's drug receives approval for additional indicationsZhitong·Oct 29, 2025 at 04:55 AM600557+1.42%
A-share weight loss drug concept stocks continued to weaken in the afternoon, Menovo hit the limit down, Medicilon and Kanion Pharmaceutical fell over 7%, SDKX and HISOAR had the largest declinesWallstreetcn·Aug 28, 2025 at 12:16 AM603538+3.04%600557+1.42%
The three major A-share indices rose collectively, with a significant increase in the biopharmaceutical sector. CPO continues to squeeze shorts, while Hong Kong stocks fluctuated and fell, tech stocks retreated, and government bonds and commodities declinedWallstreetcn·Aug 19, 2025 at 03:25 AM002873+2.54%600557+1.42%
Kanion Pharmaceutical: Clinical trial for Jianpi Shugan Guben Granules approvedZhitong·Aug 18, 2025 at 04:19 AM600557+1.42%
The traditional Chinese medicine concept continues to strengthen, with Layn hitting the daily limit, and companies such as Zhongsheng Pharmaceutical, Kanion Pharmaceutical, JINGXIN, Zhendong Pharmacy, CONBA, and Chase Sun also risingZhitong·Aug 11, 2025 at 08:36 PM600572+0.46%300026+0.60%
Kanion Pharmaceutical: Obtained the registration certificate for Canpu GranulesZhitong·Aug 3, 2025 at 03:43 AM600557+1.42%
Kanion Pharmaceutical received the clinical trial approval notice for KYS2301 gelZhitong·Jul 3, 2025 at 04:38 AM600557+1.42%
Xiao Wei resigns as Chairman of Kanion Pharmaceutical, stepping back to "cultivate successors"Zhitong·Jun 20, 2025 at 09:11 AM600557+1.42%
Kanion Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 83.413 million yuan, a year-on-year decrease of 38.37%Zhitong·Apr 29, 2025 at 06:55 AM600557+1.42%
Kanion Pharmaceutical: Obtained the drug registration certificate for Yunu Jian granulesZhitong·Apr 27, 2025 at 03:52 AM600557+1.42%
Kanion Pharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 392 million yuan, a year-on-year decrease of 15.58%Zhitong·Apr 2, 2025 at 05:46 AM600557+1.42%
Kanion Pharmaceutical received the clinical trial approval notice for Lian Shen Menopausal GranulesZhitong·Mar 27, 2025 at 03:24 AM600557+1.42%
National People's Congress representative and Chairman of Kanion Pharmaceutical, Xiao Wei: Classic Chinese medicine formulas need to be "awakened" and also "renewed"Zhitong·Mar 6, 2025 at 07:10 AM600557+1.42%
Kanion Pharmaceutical: Gu Ben Xiao Zhen Granules has obtained approval for clinical drug trialsZhitong·Mar 4, 2025 at 03:01 AM600557+1.42%
